Cafepharma Today

May 21 2025 - Medtronic plans to separate its diabetes business into a new company
Medtronic plans to separate its diabetes business into a new company
Moderna shares down after pulling Covid-flu combo vaccine application
Roche's Genentech sticks with Orionis in 2nd molecular glue deal worth $2B
RFK Jr. takes fire in Senate hearing on research cuts
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

AstraZeneca's Prescription for Growth
Yahoo/TheStreet.com
Wednesday, February 5, 2014 - 8:50am
tags:
AstraZeneca, earnings
Merck Accelerates Cancer-Immunotherapy Program With Three Collaborations
TheStreet.com
Wednesday, February 5, 2014 - 8:42am
tags:
cancer immunotherapy, Merck, Amgen, Incyte, Pfizer, Bristol-Myers Squibb, MK-3475
2014: A Billion Dollar Year For Jazz Pharmaceuticals
Seeking Alpha
Wednesday, February 5, 2014 - 8:40am
tags:
Jazz Pharmaceuticals
Smith & Nephew Becomes Pharma Family Factor
TheStreet.com
Wednesday, February 5, 2014 - 8:39am
tags:
devices, Smith & Nephew, recalls
Lupin Sees Drug Sales Opportunity From FDA Curbs on Ranbaxy
Bloomberg
Wednesday, February 5, 2014 - 8:38am
tags:
India, Lupin, Ranbaxy, FDA
Ranbaxy narrows Q4 loss on U.S. acne drug sales, shares rise
Yahoo/Reuters
Wednesday, February 5, 2014 - 8:35am
tags:
earnings, Ranbaxy
GSK optimistic as sales beat forecasts
CNBC
Wednesday, February 5, 2014 - 8:34am
tags:
GSK, earnings
Merck Earnings Miss Estimates on Diabetes Drug Slump
Bloomberg
Wednesday, February 5, 2014 - 8:31am
tags:
Merck, earnings
Eager biotechs crowd into Wall Street this week with $500M in IPO pitches
Fierce Biotech
Tuesday, February 4, 2014 - 7:06pm
tags:
IPOs, biotechs, uniQure, ReVance, Eleven Biotherapeutics
Eisai readies applications for thyroid cancer drug after SFJ delivers PhIII success
Fierce Biotech
Tuesday, February 4, 2014 - 7:05pm
tags:
Eisai, Lenvatinib, thyroid cancer, SFJ Pharmaceuticals
Gilead posts higher profit, strong hepatitis C drug sales
Yahoo/Reuters
Tuesday, February 4, 2014 - 7:01pm
tags:
Gilead Sciences, earnings
Sanofi announces Nasacort now available in U.S. without prescription
The Fly on the Wall
Tuesday, February 4, 2014 - 7:00pm
tags:
Sanofi, Nasacort
AbbVie's Challenge to Gilead in Hepatitis C Therapies
Motley Fool
Tuesday, February 4, 2014 - 7:00pm
tags:
AbbVie, Gilead Sciences, Sovaldi, hepatitis C, Enanta Pharmaceuticals, ABT-450
Could These Potential Catalysts Drive Lilly Higher?
Motley Fool
Tuesday, February 4, 2014 - 6:58pm
tags:
Eli Lilly, Evista, Zyprexa, Cymbalta, generics, solanezumab, Alzheimer's disease, LY2963016, diabetes, empagliflozin, dulaglutide
Why Merck Will Move the Dow Tomorrow
Motley Fool
Tuesday, February 4, 2014 - 6:56pm
tags:
Merck, earnings
Glaxo’s Advair Loses U.S. Market Share to Astra, Merck
Bloomberg
Tuesday, February 4, 2014 - 6:54pm
tags:
GSK, Advair, AstraZeneca, Merck, COPD
Pfizer approved for Prevenar 13 USPI to include expanded use
Yahoo/Fly on the Wall
Tuesday, February 4, 2014 - 10:33am
tags:
Prevnar 13, Pfizer, vaccines
PDL Biopharma: Agreement With Genentech And Roche Is A Net Negative
Seeking Alpha
Tuesday, February 4, 2014 - 9:58am
tags:
PDL Biopharma, Roche, Genentech, Avastin, Herceptin, Lucentis Xolair, Kadcyla, Perjeta, Lucentis
A Deeper Look At Arena Anti-Obesity Sales
Seeking Alpha
Tuesday, February 4, 2014 - 9:57am
tags:
Arena Pharmaceuticals, obesity, Eisai, Belviq
FDA rejects RedHill's and IntelGenx's migraine drug
Yahoo/Reuters
Tuesday, February 4, 2014 - 9:32am
tags:
FDA, Redhill Biopharma, migraines, IntelGenx, RHB-103

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline
Lose Your Crystalline Form and Go Amorphous
In the Pipeline
Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.